With its two-year federal probationary period coming to an end, the Wall Street Journal reports that the dark clouds [1] may be lifting from Bristol-Myers Squibb. An earnings report from BMS is due on Thursday, and analysts are expecting some word on the company's search for a new CEO. Investors are also looking for some insight into the damage done by the temporary sale of a generic competitor to Plavix. Report [2] (WSJ sub. req.)
Links:
[1] http://www.fiercebiotech.com/story/more-details-emerge-on-secret-plavix-pact/2006-08-18
[2] http://online.wsj.com/article/SB117728687233778490.html?mod=health_home_stories